Caplin Point Laboratories logo

Caplin Point Laboratories

CAPLIPOINT NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹20,471 Cr
Volatility
Moderate
P/E Ratio
30.07
EBITDA
₹876 Cr
Return on Equity
17.89%
Debt to Equity
0.07
Book Value
₹443.33
EPS
₹62.84
52W High
₹2,990
52W Low
₹1,500.3

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has delivered good profit growth of 21.4% CAGR over last 5 years
  • Company's median sales growth is 19.9% of last 10 years

Growth Rate

Revenue Growth
13.22% lower than 3Y
Net Income Growth
20.07% higher than 3Y
Cash Flow Change
21.02% lower than 3Y
ROE
-4.59% lower than 3Y
ROCE
-5.91% higher than 3Y
EBITDA Margin (Avg.)
4.13% lower than 3Y

AI Analysis — Bull vs Bear

5d ago
AI opinion · based on fundamentals
Risk medium

Caplin Point Laboratories has a market capitalisation of about ₹21,444 crore and trades at a P/E of 32.1x and a P/B of 6.46x. It is almost debt free and has earned a return on equity of 21-25% over one to ten years. Profit has compounded at 21% over 5 years and 18% on a trailing twelve-month basis. Growth has slowed from its 10-year pace (sales 25% CAGR, profit 30% CAGR), and the stock's 41% 3-year CAGR has run well ahead of its 19% 3-year profit CAGR.

Bull Case 7
  • The balance sheet is almost debt free. That gives room to fund capacity expansion and entry into regulated markets without leverage risk, which matters for a company with a ₹21,444 crore market cap.
  • Profitable growth has been steady. Profit compounded at 21% over 5 years, 19% over 3 years and 18% over the trailing twelve months, and profit has grown faster than sales in every period shown (for example, 21% profit vs 16% sales over 5 years). That points to operating leverage or margin improvement.
  • Return on equity has stayed high, at 25% over 10 years, 23% over 5 years, 22% over 3 years and 21% last year. It has not fallen below 20% in any period, and the company achieved this with almost no debt.
  • Median sales growth was 19.9% over the last 10 years, and the 10-year sales CAGR was 25%. The company has a long record of growing revenue.
  • Trailing twelve-month sales growth of 15% is slightly above the 3-year CAGR of 14%. Top-line growth appears to have steadied rather than kept slowing.
  • At a P/E of 32.1x against trailing profit growth of 18% and a 5-year profit CAGR of 21%, the price-to-growth ratio is roughly 1.5-1.8x. That is not extreme for a debt-free Indian pharma company with ROE above 20%.
  • The stock has compounded at 26% over both 5 and 10 years. This long-term return is roughly in line with 10-year profit growth of 30%, so over the long run the stock's gains have been backed by earnings growth.
Bear Case 7
  • Growth has slowed clearly over time. Sales CAGR fell from 25% (10 years) to 16% (5 years) and 14% (3 years). Profit CAGR fell from 30% (10 years) to 21% (5 years) and 19% (3 years).
  • The stock's 3-year CAGR of 41% is more than double the 3-year profit CAGR of 19%. Much of the recent return has come from the market paying a higher multiple for the same earnings, which can reverse if growth disappoints.
  • The valuation is demanding at 32.1x earnings and 6.46x book value. The implied earnings yield of about 3.1% leaves little room for execution slippage.
  • Return on equity has been drifting down, from 25% over 10 years to 23% over 5 years, 22% over 3 years and 21% last year. Returns on a growing, cash-rich equity base are easing.
  • The dividend yield is only 0.28%, so shareholders get little income. For a debt-free company, this also suggests low capital returns relative to cash generated, which can hold down ROE over time.
  • The 1-year stock return of 39% is more than double trailing profit growth of 18%. That raises the bar for coming quarters and makes the stock sensitive to any earnings miss.
  • Several standard metrics are missing from the supplied data (current ROE, ROCE, EPS, debt-to-equity and the 52-week range, which shows as 0). This limits how fully valuation and risk can be checked. Historically the business has also been concentrated in emerging markets such as Latin America, which carry currency and regulatory risk. That exposure is not quantified here.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

18h ago
Positives 1
  • ₹8 per share dividend Sep 3

    Shareholders will vote on a total dividend of ₹8 per share at the 35th AGM, set for September 25, 2026. The payout reflects steady cash generation and a commitment to shareholder returns.

Neutral 2
  • 35th AGM approves board appointments Sep 25

    Caplin Point held its 35th AGM by VC/OAVM on September 25, 2026. Shareholders re-appointed Dr. Sridhar Ganesan as MD and appointed Mr. D. Muralidharan as Whole-Time Director.

  • FY26 BRSR report filed Sep 3

    The company filed its Business Responsibility and Sustainability Report for FY26, the year ended March 31, 2026. It covers environmental metrics, workforce data and governance disclosures.

TL;DR: The recent news on Caplin Point is routine corporate governance. The AGM went through, the board appointments kept leadership continuous under MD Dr. Sridhar Ganesan, and the ₹8 per share dividend points to stable shareholder returns. None of these articles flag a negative development, but they say nothing about earnings, regulatory status or business performance, so they don't change the outlook. Look to upcoming quarterly results, progress in its Latin American markets and US FDA developments for the next real signal on the stock's direction.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
395
410
436
453
459
483
493
502
510
534
543
600
610
Expenses
269
273
293
308
307
318
331
334
332
345
353
396
397
Operating Profit
127
137
142
145
152
165
162
168
178
189
190
204
213
OPM %
32%
34%
33%
32%
33%
34%
33%
33%
35%
35%
35%
34%
35%
Other Income
12
21
17
17
19
21
31
26
23
30
34
28
34
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
11
12
14
16
16
17
16
17
16
18
19
19
22
PBT
127
146
145
146
154
168
177
177
184
201
204
213
225
Tax %
18%
20%
18%
17%
19%
22%
21%
18%
18%
20%
19%
19%
20%
Net Profit
104
116
120
121
125
131
140
145
151
160
166
173
179
EPS in Rs
13.62
15.13
15.43
16.01
16.31
17.21
18.28
18.76
20.1
20.32
21.56
22.38
23.27
Figures in ₹ Crores

Profit & Loss

Particulars Jun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
252
239
402
540
649
863
1,061
1,269
1,467
1,694
1,937
2,187
2,287
Expenses
192
175
276
345
417
603
732
874
1,025
1,142
1,287
1,422
1,491
Operating Profit
60
64
125
195
232
260
329
395
442
552
651
765
797
OPM %
24%
27%
31%
36%
36%
30%
31%
31%
30%
33%
34%
35%
35%
Other Income
3
4
10
13
19
41
23
38
55
66
92
111
126
Interest
1
0
1
1
1
0
2
1
1
1
1
1
1
Depreciation
8
7
13
19
23
32
37
47
45
53
66
73
78
PBT
53
60
121
188
227
269
314
386
451
564
677
803
844
Tax %
23%
24%
21%
23%
22%
20%
20%
20%
16%
18%
20%
19%
—
Net Profit
41
46
96
145
177
215
251
308
377
461
541
650
678
EPS in Rs
5.43
6.05
12.65
19.15
23.35
28.42
32.03
39.56
49.57
60.19
70.56
84.36
87.53
Div. Payout %
18%
20%
12%
10%
9%
9%
9%
10%
9%
8%
8%
9%
—
Figures in ₹ Crores

Balance Sheet

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
15
15
15
15
15
15
15
15
15
15
15
15
Reserves
78
113
210
349
582
858
954
1,252
1,649
2,084
2,619
3,355
Borrowings
2
2
1
1
36
113
235
219
222
219
222
221
Other Liabilities
134
137
133
136
109
139
159
250
305
380
352
446
Total Liabilities
229
267
358
500
743
1,126
1,364
1,736
2,191
2,698
3,208
4,038
Fixed Assets
113
144
152
169
227
272
305
287
280
453
546
580
CWIP
31
0
3
15
10
20
14
18
221
117
144
234
Investments
0
0
17
47
70
61
11
89
281
376
590
859
Other Assets
85
122
186
269
436
772
1,033
1,343
1,410
1,753
1,928
2,365
Total Assets
229
267
358
500
743
1,126
1,364
1,736
2,191
2,698
3,208
4,038
Figures in ₹ Crores

Cash Flow

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
50
42
68
66
83
45
269
337
271
318
432
523
Investing
-23
-6
-36
-69
-100
-54
-30
-377
-216
-319
-333
-582
Financing
-9
-14
-7
-12
90
80
-24
-41
-28
-38
-38
-46
Net Cash Flow
19
23
25
-14
73
70
215
-81
27
-39
61
-105
Free Cash Flow
24
34
43
18
18
-32
195
246
78
173
241
275
CFO/OP
103
92
73
53
54
38
102
106
81
77
86
87
Figures in ₹ Crores

Ratios

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
8
12
30
85
90
97
96
91
98
117
119
138
Inventory Days
37
57
44
44
47
210
139
149
159
183
159
181
Days Payable
112
168
155
144
76
57
68
102
84
116
103
125
Cash Conversion Cycle
-67
-99
-81
-16
61
251
166
138
173
184
175
194
Working Capital Days
-128
-114
-29
47
104
167
145
165
144
166
174
199
ROCE %
68%
62%
68%
63%
45%
33%
28%
28%
26%
26%
26%
24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Caplin Point Laboratories insights

70 extracted metrics + investor summaries across FY11–FY27.

Log in — free

Shareholding Pattern

DIIs2.49%Promot.70.57%FIIs5.75%Others6.56%Public14.62%As ofJun 2026

Documents

Frequently Asked Questions about Caplin Point Laboratories

What does Caplin Point Laboratories Ltd do?
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]
Where is Caplin Point Laboratories Ltd (CAPLIPOINT) listed?
Caplin Point Laboratories Ltd trades as CAPLIPOINT on the NSE and under code 524742 on the BSE.
Which sector does Caplin Point Laboratories Ltd belong to?
Caplin Point Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has a market capitalisation of ₹20,471 Cr, which places it in the Large Cap band.
What is the PE ratio of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd trades at a PE ratio of 30.07, on earnings per share of ₹62.84, against a book value of ₹443.33 per share.
What is the 52-week high and low of Caplin Point Laboratories Ltd?
Over the last 52 weeks Caplin Point Laboratories Ltd has traded between ₹1,500.3 and ₹2,990.
Does Caplin Point Laboratories Ltd pay dividends?
Caplin Point Laboratories Ltd has a dividend yield of 0.29%.
What is the Return on Equity (ROE) of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd reported a return on equity of 17.89%. Its debt-to-equity ratio is 0.07.

Company Information

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

Website caplinpoint.net
CEO Dr. Sridhar Ganesan
Employees 3,966
Listed 1994-11-16
Face Value ₹ 2
Issued Size 7,60,11,696

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CAPLIPOINT.md for Caplin Point Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List